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Abstract
Background: Mental retardation is a genetically heterogeneous disorder, as more than 90 genes for this disorder
has been found on the X chromosome alone. In addition the majority of patients are non-syndromic in that they
do not present with clinically recognisable features. This makes it difficult to determine the molecular cause of this
disorder on the basis of the phenotype alone. Mutations in KDM5C (previously named SMCX or JARID1C), a gene
that encodes a transcriptional regulator with histone demethylase activity specific for dimethylated and
trimethylated H3K4, are a comparatively frequent cause of non-syndromic X-linked mental retardation (NS-XLMR).
Specific transcriptional targets of KDM5C, however, are still unknown and the effects of KDM5C deficiency on gene
expression have not yet been investigated.
Results: By whole-mount in situ hybridisation we showed that the mouse homologue of KDM5C is expressed in
multiple tissues during mouse development.
We present the results of gene expression profiling performed on lymphoblastoid cell lines as well as blood from
patients with mutations in KDM5C. Using whole genome expression arrays and quantitative reverse transcriptase
polymerase chain reaction (QRT-PCR) experiments, we identified several genes, including CMKOR1, KDM5B and
KIAA0469 that were consistently deregulated in both tissues.
Conclusions: Our findings shed light on the pathological mechanisms underlying mental retardation and have
implications for future diagnostics of this heterogeneous disorder.
Background
Moderate to severe mental retardation (MR) affects 0.5%
of the population in developed countries, and in about
10% of these patients the causative mutations are
thought to be located on the X chromosome [1]. Based
on the phenotype, X-linked mental retardation (XLMR)
is often subdivided into syndromic forms characterised
by additional clinical symptoms and non-syndromic
forms where MR is the only clinically consistent feature
(NS-XLMR). Non-syndromic forms seem to be more
prevalent and they show a high degree of genetic het-
erogeneity; defects in >30 genes have been reported in
patients with NS-XLMR.
In the absence of specific clinical phenotypes, these
individual disease entities can only be distinguished by
molecular studies. However, sequencing a large number
of candidate genes to identify the underlying molecular
defects is too costly and time consuming for routine
diagnostics, at least with the currently employed metho-
dology [2]. Moreover, very often this approach will not
discriminate between disease-causing mutations and
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functionally neutral changes. This is a crucial issue
because in a majority of cases, the resequencing of can-
didate genes leads to the detection of missense changes
with unclear functional relevance, as shown by a recent
study of >700 Vega-annotated X-chromosomal genes in
a cohort of 200 NS-XLMR patients [3]. Tests, however,
that are suitable for discerning disease-causing muta-
tions are only available for a small minority of the
known NS-XLMR genes so far. However, if such tests
do not exist, gene expression profiling is an alternative,
provided the candidate gene is expressed in accessible
cells or tissues. Such an approach has been pioneered
by Cheung et al. [4] who found recognisable expression
changes in carriers of mutations in the Nijmegen Break-
age Syndrome gene, even though this gene is not
directly involved in transcription. In contrast KDM5C
(also known as JARID1C and SMCX), one of the more
frequently mutated genes in XLMR [5-8], encodes a
transcription factor that possesses several DNA binding
motifs and shows histone demethylation activity specific
for dimethylated and trimethylated lysine 4 of histone
H3 [9-11]. Overexpression studies using a range of
KDM5C cDNA constructs with different previously
reported mutations revealed reduced histone demethy-
lase activity [10,11] (Additional file 1). Reduction of
demethylase activity should have transcriptional conse-
quences [11], but specific transcriptional targets and
effects of KDM5C deficiency are not yet known. We
therefore performed whole genome expression profiling
and quantitative reverse transcriptase polymerase chain
reaction (QRT-PCR) experiments using RNA from lym-
phoblastoid cell lines or blood from patients carrying
loss of function mutations or potentially damaging mis-
sense changes in KDM5C. We have identified several
genes that are deregulated in the absence of KDM5C
function shedding more light on the function of
KDM5C in gene regulation. Moreover, we found that
these patients have specific gene expression signatures,
which could be used to assess the pathogenic nature of
DNA changes in KDM5C.
Results
Whole mount in situ hybridisation in mouse embryos
Northern blot analysis showed expression of KDM5C in
all human tissues investigated to date, including the
brain, heart, skeletal muscle, liver, pancreas and lung
[5]. To investigate expression in a wider range of mam-
malian tissues we performed whole mount in situ hybri-
disation on mouse embryos using a KDM5C specific
probe (Additional file 2a-d), which revealed widespread
expression at all investigated developmental stages
(Theiler stages TS12, TS15, TS17 and TS18). At TS21
(embryonic day 12.5) we performed sagittal section
hybridisations and observed higher expression levels in
several neuronal tissues including the spinal ganglia, the
neural ectoderm, differentiated neurons of the spinal
cord and the telencephalon as well as in the liver and
the heart (Additional file 2e, f).
Gene expression analysis
KDM5C is a transcription factor. As such it is likely that
deleterious changes in KDM5C give rise to specific tran-
scriptional effects, which might help to explain why they
are disease causing. To search for deregulated tran-
scripts we performed genome-wide expression analysis
using Epstein Barr virus (EBV) transformed patient B
lymphocytes (LCL). The patient cell line used for this
initial expression-profiling step was obtained from a
patient carrying KDM5C Trp1288Ter mutation. We
have previously shown that this mutation leads to
reduced KDM5C expression [5]. Subsequently we indivi-
dually compared the expression profile of this LCL with
each one of three different controls and extracted highly
expressed genes (detection threshold >0.99), which also
showed strong differential expression (differential
expression score of >50) and excluded genes that
showed less than twofold difference in the expression
level between patient and control cell lines. This led to
the identification of 21 genes that showed consistent dif-
ferential expression (Table 1). In addition, we found that
three other genes also showed strong differential expres-
sion between the patient and two of the three controls
from the analysis: KDM5B (also known as JARID1B),
RPS6KA3 and MKNK2.
Subsequently we performed QRT-PCR for all 24 genes
using RNA from the original patient lymphoblastoid cell
line plus 3 control lymphoblastoid cell lines and con-
firmed our observations from the array analysis for 22
out of 24 genes. Only two genes (Hs. 136376 and Neu-
rog2) did not yield the minimum amount of PCR pro-
duct required for quantitative measurements, due to
extremely low expression levels.
To further validate this set of 22 genes we expanded
the QRT-PCR analysis to 12 lymphoblastoid cell lines
from unrelated patients with KDM5C mutations and 5
controls. Quantified Northern blot analyses for the four
differentially expressed genes (CMKOR1, MKNK2, MYC
and KDM5B) confirmed the original findings (Additional
file 3). Of the 12 patients, 4 carried premature termina-
tion codon (PTC) mutations and 8 had missense muta-
tions [5,7]. The protein truncating mutations are most
likely to cause a loss of KDM5C function. The patho-
genic relevance of missense mutations, however, is more
difficult to assess. To perform the analysis we grouped
our QRT-PCR data according to mutation type, analysed
the results separately and then searched for commonly
deregulated genes. Of the 22 genes identified by array
analysis and confirmed by QRT-PCR, 7 genes were sig-
nificantly deregulated (Student t test: P < 0.05) in both
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groups (Table 2) while 5 genes showed expression dif-
ferences that depended on the nature of the KDM5C
mutation (missense or truncating).
mRNA expression profiling as a diagnostic tool
We were interested to investigate whether there was a
gene expression signature typical and discriminatory for
the disease-causing changes in KDM5C.
To test the hypothesis, we developed and performed
the method of statistical weighted accumulative permu-
tation analysis for differentiation between groups
(WAPDG). The results of this analysis showed that the
observations from some individual genes were not sig-
nificantly different between patients and controls (Figure
1a). However, the combined expression data from all 11
upregulated genes (see Table 2) were significantly differ-
ent and allowed us to distinguish patients from controls
with a high degree of confidence (P < 0.001) (Figure 1b).
These data also suggests that even smaller subsets of the
selected genes (for example, CETP, CMKOR1, EMILIN2,
HSPA1B, MYC and SLAMF6) are sufficient to differenti-
ate between patients and controls at a significance level
of P < 0.001 (Figure 1b).
To test the discriminatory power of our gene expres-
sion signature and to evaluate whether the expression
levels of these genes are sensitive to cell culture hand-
ling, we applied our approach in a blind study, using
lymphoblastoid cell lines from two unrelated patients
with recently ascertained novel KDM5C mutations [12]
and two additional controls, all of which had been
grown in a different laboratory. The WAPDG method
allowed us to correctly assign the two controls and to
unequivocally determine patient status for one sample
(NP1). The remaining patient’s (MRX13) expression sig-
natures could not be assigned to either control or
patient groups (Figure 1c).
Since the selection of genes used in this study had so
far been based on the expression profiling results from a
single patient and three controls, we also wanted to
determine whether the selected genes were among the
most highly differentially expressed in additional
patients and controls. We therefore compared our
results with genome-wide expression analyses of all 12
Table 1 21 genes selected for expression studies by QRT-
PCR.
DS>100 DS>50
DT>0.99 DT = 1
Hs.136376 OXTR
MGC20983 SLAMF6
APM2 MSL3L1
MYC KIAA0469
CETP SLC1A4
LOC148918
CMKOR1
MSL3L1
SQSTM1
CD55
EMILIN2
NEUROG2
HSPA1B
CABP1
OAS3
TNFSF4
DS: Differential score, DT: detection threshold
Table 2 Differentially expressed genes in lymphoblastoid cell lines from MR patients with changes in KDM5C.
Missense change Truncating mutation
Symbol Protein RefSeq ID Ratioa Significanceb Ratioa Significancec
CETPd cholesteryl ester transfer protein, plasma NM_000078.1 4.34 NS 8.57 *
CD55e decay accelerating factor for complement NM_000574.2 2.03 * 1.88 NS
CMKOR1f chemokine orphan receptor 1 NM_020311.1 6.85 ** 6.29 *
EMILIN2f elastin microfibril interfacer 2 NM_032048.1 2.34 *** 2.49 ***
HSPA1Be heat shock 70 kDa protein 1B NM_005346.3 4.00 * 2.66 NS
KDM5Be lysine (K)-specific demethylase 5B NM_006618.2 3.18 *** 1.94 NS
KIAA0469d KIAA0469 XM_375685.1 1.52 NS 1.74 *
MGC20983f hypothetical protein LOC115948 NM_145045.3 2.72 * 2.94 *
MKNK2f MAP kinase-interacting serine/threonine kinase 2 NM_017572.2 2.07 * 2.40 **
MYCf myc proto-oncogene protein NM_002467.2 2.54 ** 2.89 **
SLAMF6f activating NK receptor precursor NM_052931.3 2.71 ** 2.41 *
TNFSF4f tumor necrosis factor (ligand) superfamily NM_003326.2 0.20 ** 0.12 **
NS: Not significant; *: P < 0.05; **: P < 0.01; ***: P < 0.001
a) Ratio was calculated as the mean expression divided by mean control expression
b) Level of significance was calculated by students’ t-test using expression data from carriers of missense changes (n = 8)
c) Level of significance was calculated by students’ t-test using expression data from carriers of truncating mutations (n = 4)
d) Genes significantly deregulated in truncating mutation carriers
e) Genes significantly deregulated in missense change carriers
f)7 genes that are significantly deregulated for both mutation types are marked in bold
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patients and 5 controls. The results of these experiments
validated our original selection of marker genes, as they
showed that with the exception of MKNK2 all pre-
viously selected and analysed genes were among the top
1% of significantly deregulated genes in the expanded
group of patients.
Differential mRNA expression in whole blood from MR
patients and obligate carriers
To further validate the gene expression signature
obtained from lymphoblastoid cell lines we performed
QRT-PCR on mRNA isolated from whole blood from
affected members of two families. These families (D034
and D029) carry a protein truncating mutation
(R68fsX7) and a missense change (Glu698Lys), respec-
tively [5] (Figure 2). As controls we used RNA extracted
from the blood of five healthy male individuals.
In all, 10 out of 12 genes that were differentially
expressed in LCLs were also found to be expressed in
blood and 3 of these (CMKOR1, KDM5B and
KIAA0469) were significantly upregulated (P < 0.05, Stu-
dent t test) in all affected individuals from both families
(Table 3).
Figure 1 Weighted accumulative permutation analysis for differentiation between groups (WAPDG) results. (a) Means of the 1,000-fold
permutated expression values per gene in patients and controls. (b) Results of summarised analysis including different subsets of genes. (c)
Results of WAPDG analysis of two novel patients (NP1 and MRX13) and two novel controls (NC1 and NC2). The error bars represent the SD.
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Discussion
In this study we performed genome-wide gene expres-
sion analyses in order to identify genes that are signifi-
cantly upregulated or downregulated in LCLs and blood
from patients with mutations in the transcription factor
KDM5C. This led to the identification of 12 genes that
are significantly deregulated in patient LCLs. Seven
genes were consistently deregulated in LCLs from
patients with missense and nonsense mutations and it is
tempting to speculate that deregulation of at least some
of these putative KDM5C targets is involved in the
aetiology of MR in the patients.
Most of the differentially expressed genes observed in
the genome-wide analysis show upregulation in patient
LCLs. This is remarkable, as the proportion of genes
with elevated expression exceeds by far what had to be
expected due to the normal detection bias towards upre-
gulated genes in such experiments, and it suggests that
KDM5C acts primarily as a transcriptional repressor,
which is in fact in line with recent studies reporting
repression of Smad3 activity by KDM5C [13].
The seven missense changes investigated in this study
have, for all but one, been shown to result in reduced
demethylase activity in vitro or in altered cellular locali-
sation [10,11]. The remaining missense change
(Arg750Trp) is located in the C5HC2 zinc finger
domain, immediately adjacent to a missense change
(Tyr751Cys) with a known effect on demethylase activity
[10] and can thus be assumed to cause a similar impair-
ment of KDM5C function. All these missense changes
are therefore very likely causative mutations. The
expression pattern of the 12 selected genes in these
missense changes also correlates better with that of the
cell lines with truncating mutations than with that of
the controls. For several genes (CD55, CMKOR1,
HSPA1B, KDM5B, and SLAMF6) missense changes
seem to have a stronger effect on the expression level
changes as compared to truncating mutations. This
might be due to negative gain of function effects where
mutated KDM5C could, for example, obstruct other
demethylase enzymes in compensating for the loss of
physiological KDM5C function. Therefore, expression
profiling may be a valuable tool for testing the relevance
of missense changes in KDM5C as patients with muta-
tions in KDM5C do not necessarily present with other
consistent, clinically identifiable features. From a practi-
cal and diagnostic point of view this approach may be
more feasible than using currently available histone
demethylase assay, which involves cloning and mass
spectrometry.
It appears that the expression profile we identified
correlates with the severity of the molecular and/or clin-
ical patient phenotype. This became evident in two
cases where the expression profile did not allow unequi-
vocal assignment of the affected status, namely the
patient from family MRX13 (Figure 1c) and the patient
from P081 with a Phe642Leu change. In these two cases
our gene expression results reflect the relatively mild
impairment of histone 3 lysine 4 demethylase activity
[10] observed in the patient carrying the Phe642Leu
change and the intermediate clinical phenotype observed
in MRX13 [12].
LCLs were previously shown to provide a useful
model for the investigation of the expression of genes
that are relevant in human cognition [14]. However, as
whole blood is more easily accessible in a diagnostic set-
ting we compared the expression patterns obtained from
LCLs with those observed in blood-derived RNA pre-
parations from patients of two families with different
KDM5C mutation types. We thus found that KDM5B,
CMKOR1 and KIAA0469 were consistently upregulated
in LCLs as well as whole blood from all affected indivi-
duals. KDM5B is particularly interesting because it
encodes a histone 3 lysine 4 demethylase that is highly
similar to KDM5C [9,15]. It is therefore possible that
KDM5B can partially compensate for KDM5C deficiency
in most tissues, but not in a manner that is sufficient to
ensure normal brain development and function. This
could explain why the patients do not show any other
clinical features apart from MR.
The second gene consistently deregulated in blood
and LCLs from patients with KDM5C mutations is the
chemokine receptor-encodinggene CMKOR1/CXCR7.
Upregulation of this gene has also been found in lym-
phoblastoid cell lines from autistic patients with FMR1
mutations or 15q11-q13 duplications [14]. Interestingly,
Figure 2 mRNA expression in whole blood from two mental
retardation (MR) families. The pedigrees of two MR families for
which whole blood was obtained are shown. Affected members of
family D034 carry the frameshift mutation R68fsX7 and affected
members of family D029 carry a Glu698Lys missense mutation.
Numbers indicate the individuals from whom whole blood was
obtained for RNA extraction.
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several other genes that we found to be deregulated in
KDM5C deficient cell lines showed similarly, albeit less
significantly altered expression in a previous study [14].
These genes include GPR155 (G protein coupled recep-
tor 155), PITPNC1 (phosphatidylinositol transfer pro-
tein, cytoplasmic, 1), LCP2 (lymphocyte cytosolic
protein 2) and HIG2 (hypoxia-inducible protein 2).
Together with the recent finding of a KDM5C missense
change in a patient with autism spectrum disorder [8],
our findings suggest that autism and non-syndromic
MR may overlap at the phenotypical as well as the
molecular level.
KIAA0469/KLHL21 (Kelch-like 21) encodes a brain
expressed but otherwise uncharacterised protein. Other
members of the KLHL family of proteins are involved in
protein degradation [16] and in neurite outgrowth [17].
Since proper functioning of the central nervous system
depends on the unperturbed formation of interneuronal
connections, our observation that KIAA0469/KLHL21 is
deregulated in MR patients with KDM5C mutations
strongly suggests that its function is similar to that of
the other members of the KLHL family. This result pro-
vides a starting point for future research into the func-
tion of KIAA0469/KLHL21 and also suggests that
KDM5C deficiency may involve neurite outgrowth.
Conclusions
We have shown that KDM5C is ubiquitously expressed
during the early stages of mammalian ontogenesis and
provide data describing the transcriptional effects of
KDM5C deficiency in both lymphoblastoid cell lines and
whole blood from mutation carriers and healthy
individuals. Our study points out the potential of
expression profiling for diagnostic purposes in XLMR,
by providing a method for testing the pathogenic rele-
vance of missense mutations in this gene. Finally our
results shed light on the function of KDM5C as a tran-
scriptional repressor and open up new avenues of
research for elucidating the causes of mental retardation
in patients with KDM5C deficiency.
Methods
Patients
Lymphoblastoid cell lines from the index patients of 12
different MR families were used in this study. Blood was
obtained from members of the MR families D029 and
D034 carrying a Glu698Lys and an R68fsX7 mutation,
respectively. All patients had NS-XLMR without consis-
tent additional features and have been described else-
where [5,7]. For all affected families with patients
carrying missense changes, cosegregation with the disor-
der had been shown except for family P081, where no
other family members were available [5,7].
The probands or their parents gave their written
informed consent to these investigations. The study was
approved by the institutional review board of the Uni-
versity Hospital Berlin (Charité), Berlin, Germany.
Mouse in situ hybridisation
A PCR fragment of 825 base pairs (bp), corresponding
to position 4,416 to 5,240 of the mouse NM_013668.2
reference sequence was amplified from cDNA using the
primers: Smcx_ISH_1f 5’-GGTACGAAGCTCAGGAC
CAG-3’ and Smcx_ISH_1r 5’-GACAAGCACCAAA
AGCCTTC-3’. The PCR product was cloned using the
Table 3 Differential mRNA expression in whole blood from MR patients.
Missense change Truncating mutation
Symbol Sequence ID Ratioa Significanceb Ratioa Significancec
CETPd cholesteryl ester transfer protein, plasma NM_000078.1 ND ND
CD55e decay accelerating factor for complement NM_000574.2 7.50 ** 1.00 NS
CMKOR1f chemokine orphan receptor 1 NM_020311.1 6.30 *** 3.40 ***
EMILIN2 elastin microfibril interfacer 2 NM_032048.1 1.18 NS 0.82 NS
HSPA1Be heat shock 70 kDa protein 1B NM_005346.3 2.71 * 1.34 NS
KDM5Bf lysine (K)-specific demethylase 5B NM_006618.2 3.74 *** 1.58 *
KIAA0469f KIAA0469 XM_375685.1 3.22 *** 2.04 **
MGC20983d hypothetical protein LOC115948 NM_145045.3 ND ND
MKNK2e MAP kinase-interacting serine/threonine kinase 2 NM_017572.2 3.65 *** 1.27 NS
MYC myc proto-oncogene protein NM_002467.2 1.20 NS 0.75 NS
SLAMF6 activating NK receptor precursor NM_052931.3 1.09 NS 1.08 NS
TNFSF4e tumor necrosis factor (ligand) superfamily NM_003326.2 1.66 * 0.99 NS
ND: Not determined; NS: Not significant; *: P < 0.05; **: P < 0.01; ***: P < 0.001
a) Ratio was calculated as the mean expression from affected in the family divided by mean control expression
b) Level of significance was calculated by students’ t-test using expression data from patients with missense a change (n = 2) and controls (n = 5)
c) Level of significance was calculated by students’ t-test using expression data from patients premature termination (n = 2) and controls (n = 5)
d)Genes with too low expression for reliable QRT-PCR evaluation
e) Genes significantly deregulated in missense change carriers
f) 3 genes that are significantly deregulated in affected from both families are marked in bold
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pGEM-T Easy Vector System I (Promega, Madison, WI,
USA) according to the manufacturer’s instructions. The
vector was linearised and purified prior to sense and
antisense in vitro transcription in the presence of digoxi-
genin-UTP (DIG RNA Labeling Kit (SP6/T7), Roche
Applied Sciences, Penzberg, Germany).
Whole mount in situ hybridisations were carried out
according to a previously published protocol [18]. Sec-
tion in situ hybridisation was performed on fresh frozen
tissue employing the TECAN GenePaint system as pre-
viously described [19].
The experimental procedures that involved mice were
approved by the ‘Landesamt für Gesundheitsschutz und
Technische Sicherheit’ (LaGeTSi), Berlin, Germany.
RNA isolation from patient lymphoblastoid cell lines
Total RNA from lymphoblastoid cell lines was isolated
using the Trizol reagent (Invitrogen, Carlsbad, CA,
USA). Whole blood was collected and total RNA
extracted using the PAXgene Blood RNA System
according to the instructions of the manufacturer (PreA-
nalytiX, Hombrechtikon, Switzerland). The RNA was
checked for integrity on ethidium bromide stained agar-
ose gels and the concentration was measured with a
NanoDrop ND-1000 Spectrophotometer (NanoDrop
Technologies, Wilmington, DE, USA).
Microarray hybridisation and data analysis
Total RNA (300 ng) from an LCL with a nonsense
mutation in KDM5C (Trp1288Ter) and three control
cell lines were converted into double stranded, T7 pro-
moter-containing cDNA and transcribed in the presence
of biotin using the Illumina TotalPrep RNA Amplifica-
tion Kit (Ambion, Austin, TX, USA). The labelled cRNA
was hybridised to the Sentrix Human-6 Expression
Beadchip, which contains probes for >48,000 transcripts
(see http://www.illumina.com/ for detailed information).
After hybridisation, washing and Cy3-streptavidin
(Amersham Biosciences, Piscataway, NJ, USA) staining,
the arrays were scanned using an Illumina BeadStation
500 (Illumina, San Diego, CA, USA). The Illumina Bead-
Studio software was used for analysis and we applied the
‘rank invariant’ algorithm for normalisation of the
expression data.
All micro array data is ‘Minimum Information About
a Microarray Experiment’ (MIAME) compliant and
stored under the GEO series access number GSE8252
http://www.ncbi.nlm.nih.gov/geo/. Using the Illumina
Sentrix Human-6 v2 platform RNA from 12 patients
with mutations in KDM5C and 5 control lymphoblas-
toid cell lines were analysed.
cDNA synthesis, QRT-PCR and data evaluation
For use in quantitative PCR 1 μg total RNA was reverse
transcribed in the presence of 1.5 microgram random
hexamers pdN6 (Invitrogen, Carlsbad, CA, USA) and
0.33 mM deoxyribonucleotide triphosphate (dNTP) in a
total volume of 30 μl using the Roche (Mannheim, Ger-
many) First Strand cDNA Synthesis Kit. Primers for
quantitative RT-PCR were designed by Primer3 software
(http://frodo.wi.mit.edu/primer3/; sequences are avail-
able upon request). Whenever possible, the amplified
cDNA fragments were intron spanning and included the
probe sequence from the expression array. PCRs were
performed in triplicates of 10 or 30 μl reactions in the
presence of SYBR green (Applied Biosystems, Foster
City, CA, USA). Quantitations were performed using the
absolute quantification setting and a standard curve gen-
erated by serial dilution (factor 2) of cDNA.
All calculations for testing differences between groups
of patients and controls were performed with the GLM
procedure in SAS V.8 (SAS Institute, Cary, NC, USA).
Each model included distinct classes of MR patients and
the control group as discontinuous independent variable
(fixed effect). Since we used one-factorial models no
adjustments were performed. Least squares (LS) mean
differences were tested by Student t test and the prob-
abilities were calculated for the hypothesis H0:LSM(i) =
LSM(j).
WAPDG
WAPDG is an analysis for differentiation between dis-
tinct predefined groups by summarising permutated
data from weighted expression values of different genes.
Patients and controls were considered as separate
groups. For the generation of equally weighted gene
expression information, the individual expression values
were divided by the total mean of expression values
(both groups combined) per gene.
From these data the mean values and SDs per group
were used to generate 1,000 permutations per gene for
normal distributed expression values within groups
based on the ‘ran1’ and ‘gasdev’ functions from scientific
routines [20] considering only values > 0. This led to a
slight positive skew in the distribution of permutation
values, which reflected the distribution of the original
observations.
For each gene as well as for the combination of all
genes the proportion of shared values between groups
was determined.
Northern blot analysis
For Northern blot analyses, poly-A+ RNA was isolated
from 75 microgram total RNA by oligo(dT) magnetic
bead-based purification (Dynal Biotech, Oslo, Norway).
The RNA was separated on a formaldehyde containing
gel in 1 × MOPS (Sigma Aldrich, Steinheim, Germany),
transferred to a Hybond N+ membrane, and crosslinked
by UV light using the autocrosslink settings of a Strata-
linker (Stratagene, La Jolla, CA, USA). Probes with an
average size between 600 and 1,000 bp were designed to
hybridise to the 3’ region of the target RefSeq cDNA
and PCR amplified from genomic DNA (primer
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sequences are available upon request). The specificity of
the probes was verified by BLAST alignment http://
blast.ncbi.nlm.nih.gov/Blast.cgi. The 32 [P]dCTP labelled
fragments were purified and hybridised to membranes
in UltraHyb buffer (Ambion, Austin, TX, USA) and
washed according to the manufacturer’s instructions.
Subsequently, Northern blots were analysed using a
Storm 820 imaging system (APBiotech, Piscataway, NJ,
USA). To control for RNA loading, blots were reprobed
with a b-actin probe (BioChain, Hayward, CA, USA).
Band intensities were quantified with the ImageQuant
Version 5.2 (Molecular Dynamics, Sunnyvale, CA, USA),
using the b-actin specific band for normalisation.
Additional file 1: Table S1. Influence of mutations in KDM5C on
demethylase activity.
Click here for file
[ http://www.biomedcentral.com/content/supplementary/1755-8417-3-2-
S1.DOC ]
Additional file 2: JARID1C mRNA expression in the mouse embryo.
Expression of JARID1C as detected in whole mount in situ hybridisation
at (a) Theiler stage (TS)12, (b) TS15, (c) TS17, and (d) TS18. Expression of
JARID1C is widespread with highest levels in the surface ectoderm, in
rostral branchial arches (BA), frontonasal process (FNP), and limb buds
(FL, forelimb bud). Higher level of expression is also detected in the
headfolds (HF) at TS12 (forebrain anlagen), and from TS17 on, in the
somites (So), in the prospective brain (MB, midbrain, Tel, telencephalon),
in head ganglia (Tri, trigeminus ganglion) and spinal ganglia (SG). From
TS18 on, higher JARID1C expression is also observed ventrally in the
rostral spinal cord (SC). Midsagittal section in situ hybridisation (E) shows
highest level of expression in telencephalon (Tel), tooth anlagen (To),
heart (Ht), liver (Li), endoderm of gut (G) and umbilical hernia (U), spinal
ganglia (SG), ventral horn of the spinal chord (SC) and in cells
surrounding the cartilaginous condensations of the vertebral column
(VC). Sagittal section hybridisation (F) shows additional expression
domains in the metanephros (Me) and olfactory epithelium (OE). The
sense probe did not give rise to signals above background levels.
Click here for file
[ http://www.biomedcentral.com/content/supplementary/1755-8417-3-2-
S2.TIFF ]
Additional file 3: Northern blot mRNA expression analysis of 4
genes in 12 patients and 5 control cell lines. The blot was
sequentially hybridised with radioactive probes. Using a Storm 820
imaging system (APBiotech, Piscataway, NJ, USA), the expression of four
genes was quantified using b-actin expression as normalisation standard.
For CMKOR1, MKNK2, MYC and KDM5B the mean expression was 3.67-
fold, 1.79-fold, 2.54-fold and 2.56-fold higher in the patient group as
compared to the control group, respectively. Using the Student t test the
level of significance was calculated to be 0.00047, 0.0022, 0.000019 and
0.016, respectively.
Click here for file
[ http://www.biomedcentral.com/content/supplementary/1755-8417-3-2-
S3.TIFF ]
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